Holen Sie sich die Stockscreener-App
0.2121
1.16%
-0.0025
Handel nachbörslich:
.21
-0.0021
-0.99%
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Now Pharma Inc looks for cure as Trump delivers dose of anxiety - The Economic Times
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fierce Biotech Layoff Tracker 2025: Relay sheds staff again; Sail lays off employees - Fierce Biotech
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - BioSpace
Ionis to present at upcoming investor conferences - Quantisnow
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN
Research Analysts Issue Forecasts for XFOR FY2028 Earnings - Defense World
X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Buy” Rating from HC Wainwright - Defense World
XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25… - Yahoo Finance
Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views - Benzinga
H.C. Wainwright maintains Buy on X4 Pharma, target at $1.50 - Investing.com
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: - GuruFocus
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Stifel cuts X4 Pharmaceuticals target to $3, maintains buy rating - Investing.com
Brookline maintains Buy on X4 Pharma, keeps $4 price target By Investing.com - Investing.com UK
X4 Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Earnings call transcript: X4 Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com
X4 Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings: Revenue Surpasses Estimates at $1.4M, EPS Misses at -$0.20 - GuruFocus
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
X4 Pharmaceuticals Announces Activation of Phase 3 4WARD Trial for Chronic Neutropenia and 2024 Financial Results - Nasdaq
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: W - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
X4 Pharmaceuticals Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Prescription Drug Costs | Pros, Cons, Debate, Arguments, Economy, Laws, Government, & Regulation - Britannica
SEC Form 10-K filed by Sionna Therapeutics Inc. - Quantisnow
Form 10-K Sionna Therapeutics, For: Dec 31 - StreetInsider.com
This Pharmaceutical Company Completes 100 per cent Acquisition of Antibe Therapeutics for CAD 4.5 Million - Dalal Street Investment Journal
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update - Defense World
Alkaptonuria Therapeutics Market to Reach US$ 31.6 Million - GlobeNewswire
Breast Cancer Clinical Pipeline | 100+ Companies, Including - openPR
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):